Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...8081828384858687888990...858859»
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Advancing Treatment Choices: CDK4/6 Inhibitor Switching in HR+/HER2- Metastatic Breast Cancer (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_484;    
    The oncologists prescribing CDK4/6i switch reported that most of these patients were in first-line treatment (85%) and the most common switch to the second CDK4/6i that was most frequently initiated was palbociclib (69%), then abemaciclib (17%) and ribociclib (14%). Our survey highlights the importance of allowing CDK4/6i switching, thus likely prompting oncologists to adapt their treatment choices, leading to better management of AEs for improving patients' outcome.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    HER2-low status in advanced breast cancer patients treated with CDK4/6 inhibitors: is it predictive of outcome? (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_479;    
    As for the endocrine compound, 240 pts were treated with letrozole, and 112 pts with fulvestrant... HER2-low status, albeit being predictive for subsequent anti-HER2 treatment modalities, was not predictive for PFS nor OS in advanced breast cancer patients treated with CDK4/6 inhibitors.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Poor response to Cyclin Dependent Kinase 4/6 inhibition in metastatic inflammatory breast cancer (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_471;    
    Patients receiving CDKI in the first vs second-line setting demonstrated a relatively superior outcome. Overall, however, outcomes are significantly inferior to historical data compared to non-IBC.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Integrated multi-omic analysis of HR+/HER2- breast cancer cell lines resistant to CDK4/6 Inhibitors. (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_306;    
    This integrated multi-omics analysis suggests that, among heterogeneous and model-specific mechanisms, modulation of ER signaling might be a common feature of resistance to CDK4/6i. At resistance, the methylation status of promoters could serve as an additional tool for assessing the modulation of the ER pathway.
  • ||||||||||  Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
    Trial completion date, Trial primary completion date:  A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer (clinicaltrials.gov) -  Mar 19, 2024   
    P2,  N=39, Active, not recruiting, 
    At resistance, the methylation status of promoters could serve as an additional tool for assessing the modulation of the ER pathway. Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion date, Trial primary completion date:  Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia (clinicaltrials.gov) -  Mar 18, 2024   
    P2,  N=15, Recruiting, 
    N=220 --> 400 | Trial completion date: Jun 2026 --> Apr 2028 Trial completion date: Dec 2026 --> Jun 2024 | Trial primary completion date: Dec 2026 --> Jun 2024
  • ||||||||||  HLX14 (denosumab biosimilar) / Fosun Pharma, Organon
    Trial completion:  Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia (clinicaltrials.gov) -  Mar 18, 2024   
    P1,  N=252, Completed, 
    Trial completion date: Dec 2026 --> Jun 2024 | Trial primary completion date: Dec 2026 --> Jun 2024 Recruiting --> Completed
  • ||||||||||  mirdametinib (PD-0325901) / SpringWorks Therap, Ibrance (palbociclib) / Pfizer
    Trial completion, Phase classification, Enrollment change, Combination therapy:  PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors (clinicaltrials.gov) -  Mar 18, 2024   
    P1,  N=60, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | N=139 --> 60
  • ||||||||||  Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
    Trial completion date, Trial primary completion date:  EDEN: Darbepoetin in Neonatal Encephalopathy Trial (clinicaltrials.gov) -  Mar 18, 2024   
    P2,  N=150, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Feb 2024 --> Sep 2024
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
    Journal, Metastases:  Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study. (Pubmed Central) -  Mar 18, 2024   
    In our study, we aimed to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment in patients with premenopausal metastatic breast cancer and the effect of dose reduction due to neutropenia on progression-free survival...Liver metastasis, using a fulvestrant together with a CDK 4-6 inhibitor, ECOG PS 1 was found to be a negative prognostic factor...In our study, we found PFS over 27?months in patients diagnosed with premenopausal breast cancer with CDK 4-6 inhibitors used in first-line treatment, similar to post-menopausal patients. We did not detect any difference between the effectiveness of the two CDK 4-6 inhibitors, and we showed that there was no decrease in the effectiveness of the CDK 4-6 inhibitor in patients whose dose was reduced due to neutropenia.
  • ||||||||||  maridebart cafraglutide (AMG 133) / Amgen
    P1 data, Journal:  Phase I results for AMG 133. (Pubmed Central) -  Mar 18, 2024   
    This suggests that MRI examination and whole exome sequencing should be considered when MCTO is suspected, and Denosumab might be an option in the treatment of MCTO. No abstract available
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal, Metastases:  Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. (Pubmed Central) -  Mar 18, 2024   
    With recovered survival data, the median OS was 53.8 (95% CI, 49.8 to 59.2) versus 49.8 months (95% CI, 42.3 to 56.4), respectively (HR, 0.92 [95% CI, 0.76 to 1.12]; one-sided P = .21). OS was not significantly improved with palbociclib plus letrozole compared with placebo plus letrozole.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Journal, Metastases:  Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival. (Pubmed Central) -  Mar 18, 2024   
    Patients achieving cCR with pCR after T-VEC therapy have the most favorable overall survival outcomes, whereas those achieving cCR without pCR have inferior survival and those achieving less than cCR have the poorest overall survival outcomes. These findings emphasize the importance of histological confirmation and provide insights for optimizing T-VEC therapy in patients with advanced melanoma.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    Enrollment closed, Phase classification, Enrollment change, Trial completion date, Combination therapy, Metastases:  Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Mar 18, 2024   
    P1,  N=34, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=72 --> 34 | Trial completion date: Mar 2024 --> Jun 2025
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion date, Minimal residual disease:  Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL (clinicaltrials.gov) -  Mar 17, 2024   
    P2,  N=2, Active, not recruiting, 
    Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2025 --> Jun 2026 Trial completion date: Nov 2024 --> Aug 2027
  • ||||||||||  Osteoarthritis or Psoriatic Arthritis? (A7) -  Mar 17, 2024 - Abstract #EULAR2024EULAR_508;    
    Previous treatments included sulfasalazine, methotrexate, adalimumab, etanercept, secukinumab, and ustekinumab.The hand arthralgia was constant, the lower back pain worse after periods of inactivity, and the neck pain worse on movement and associated with stiffness and crepitus.The patient was noted to be overweight with BMI of 29...For the first time, she now refers having mechanical thoraco-lumbar pain since she was at least 50 years old, not radiating, worsening after exercising (which she now increased) and improving with NSAID (Ibuprofen 600 mg) on demand.Complementary examinations results include HLA B27 negative test and serum acute phase reactants within normal range; imaging exams were requested and performed.Through this case we will discuss the challenges of differential diagnosis in PsA patients with spinal pain and the role of imaging exams.Case 3:Joe, a 65 years old male, was referred to the rheumatologic clinic in January 2024...His nails had a look that had never caught his attention, but nail pitting was clear. Laboratory tests showed a positive HLA B27, a negative rheumatoid factor, CRP 25 mg/L and ESR 46 mm/h.Through this case we will evaluate axial PsA as differential diagnosis at any age, and discuss clinical and imaging overlap with DISH.